Risvutatug Rezetecan for Sarcoma

This trial aims to test a new medicine called Risvutatug Rezetecan (Ris-Rez) to determine its effectiveness in treating certain types of cancer, specifically osteosarcoma (bone cancer) and soft tissue sarcoma (cancer in muscles, fat, or nerves). The study will assess the medicine's safety, tolerance, and how the body processes it. Participants will be divided into different groups; some will receive only Ris-Rez, while others will receive it combined with another drug to boost white blood cells. This trial targets individuals aged 12 and older with these cancers that have recurred or spread after previous treatment. As a Phase 1 and Phase 2 trial, the research focuses on understanding how the treatment works in people and measuring its effectiveness in an initial, smaller group.

A previous study tested the drug risvutatug rezetecan, also known as Ris-Rez, for safety and showed promising results. Most participants tolerated the treatment well. Although some side effects occurred, they were usually mild to moderate, with more serious side effects being less common.

Risvutatug Rezetecan is unique because it targets sarcoma cells in a way that could enhance the immune system's response to the cancer. Most treatments for sarcoma, like traditional chemotherapy and radiation, focus on directly killing cancer cells, but often come with significant side effects. This study drug, especially in combination with Granulocyte-Colony Stimulating Factor (G-CSF), aims to boost the body's own immune defenses, potentially leading to more effective and less toxic outcomes. Researchers are excited because this approach could represent a shift from conventional treatments, offering a more targeted and personalized therapy for patients with sarcoma.

Research has shown that Risvutatug Rezetecan, or Ris-Rez, yields promising results in cancer treatment. One study found that lung cancer patients taking Ris-Rez lived longer, with an average survival of 18.5 months compared to 10.3 months for those on another treatment. Ris-Rez also extended the time patients lived without their cancer worsening. The drug may work by targeting specific proteins on cancer cells, which can inhibit their growth. Although these results come from various cancer types, they offer hope that Ris-Rez might also be effective for sarcomas. Participants in this trial will receive Ris-Rez, with some cohorts also receiving Granulocyte-Colony Stimulating Factor (G-CSF) to potentially enhance treatment effects.¹⁶⁷⁸⁹